Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritis.
BACKGROUND
The growth of economic analyses and in particular cost-utility analyses (CUA), which use the QALY as a measure of outcome, has heightened the interest in the methodologies used to calculate the QALY. The EQ-5D has produced quite different utility values from that of the SF-6D. This article seeks to understand these differences using a cohort of patients with inflammatory arthritis.


OBJECTIVE
To examine the relationship between the disease-specific measure, Health Assessment Questionnaire (HAQ) disability index (DI) and the preference-based measures, SF-6D, EQ-5D and European League Against Arthritis (EULAR) Disease Activity Score (DAS) in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA).


METHODS
Patients with RA and PsA (n = 504) attending a tertiary rheumatology referral centre completed the HAQ, SF-6D and the EQ-5D before starting biological therapy and again 12 months later. The SF-36 was converted into a utility using the preference-based SF-6D. Clinical outcomes such as the DAS, joint counts and laboratory measures were also recorded. We calculated single index utility scores from the preference-based instruments using UK population norms. We used regression analysis to derive a mapping function and calculated utility scores from the HAQDI and the DAS 28.


RESULTS
The mean utility observed at baseline for RA was 0.43 for the EQ-5D and 0.54 for the SF-6D and for PsA was 0.49 for the EQ-5D and 0.57 for the SF-6D. The utility gain demonstrated by the EQ-5D was over twice that of the SF-6D. The EQ-5D scored 17% of the RA group as less than 0 (state defined as worse than death); 7% of this group remained less than 0 at follow-up. The distribution of the utility estimates was similar for both RA and PsA.


CONCLUSIONS
Our findings draw attention to the impact of states worse than death on the overall distribution for the EQ-5D derived utilities and how these impact on its use in practice. EQ-5D-derived QALY changes are over twice that of the SF-6D. The implication of this for decision makers is that cost-effectiveness evaluations for treatments in this disease class are likely to be very sensitive to the choice of utility measure.
Adams
Roisin
R
National Centre for Pharmacoeconomics, St. James' Hospital, Dublin 8, Ireland. radams@stjames.ie
Walsh
Cathal
C
Veale
Douglas
D
Bresnihan
Barry
B
FitzGerald
Oliver
O
Barry
Michael
M
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015535:Arthritis, Psoriatic / Q000191:economics*; D001172:Arthritis, Rheumatoid / Q000191:economics*; D003362:Cost-Benefit Analysis / Q000379:methods*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017059:Models, Econometric; D017063:Outcome Assessment, Health Care / Q000379:methods*; D019057:Quality-Adjusted Life Years; D012720:Severity of Illness Index
Rheumatology (Oxford). 2004 Jan;43(1):62-72
12890861
Ann Rheum Dis. 2010 Jan;69(1):222-5
19293160
Arthritis Rheum. 1980 Feb;23(2):137-45
7362664
Rheumatology (Oxford). 2006 Aug;45(8):1029-38
16782734
Health Econ. 2006 Nov;15(11):1229-36
16625671
Pharmacoeconomics. 2008;26(9):781-98
18767898
J Rheumatol. 1982 Sep-Oct;9(5):789-93
7175852
Med Care. 2004 Nov;42(11):1125-31
15586840
Appl Health Econ Health Policy. 2004;3(2):91-102
15702946
Rheumatology (Oxford). 2005 Sep;44(9):1169-75
15956093
Health Econ. 1996 Mar-Apr;5(2):141-54
8733106
Soc Sci Med. 2007 Mar;64(6):1242-52
17157971
Pharmacoeconomics. 2008;26(2):121-9
18198932
Mod Rheumatol. 2006;16(2):77-84
16633926
Health Qual Life Outcomes. 2008 Jul 14;6:51
18625052
Br J Rheumatol. 1996 Sep;35 Suppl 2:4-7
8810683
Arthritis Rheum. 1995 Oct;38(10):1351-62
7575685
Br J Rheumatol. 1997 May;36(5):551-9
9189057
Arthritis Rheum. 2001 Apr;45(2):151-8
11324779
Value Health. 2009 Sep;12(6):1026-34
19473335
Br J Rheumatol. 1994 Jul;33(7):655-62
8019795
Int J Technol Assess Health Care. 2009 Apr;25(2):181-9
19331709
Curr Med Res Opin. 2008 Sep;24(9):2639-50
18687164
Arthritis Rheum. 1996 Jan;39(1):34-40
8546736
Eur J Health Econ. 2005 Sep;6(3):253-60
15968563
Arthritis Rheum. 1999 Feb;42(2):347-56
10025930
Med Care. 1992 Jun;30(6):473-83
1593914
Health Technol Assess. 2004 Mar;8(11):iii, 1-91
14982655
Med Care. 2003 Jul;41(7):791-801
12835603
Ann Rheum Dis. 2005 Jul;64(7):995-1002
15550533
J Health Econ. 2002 Mar;21(2):271-92
11939242
Popul Health Metr. 2009 Jan 13;7:3
19144115
Qual Life Res. 2009 Nov;18(9):1195-205
19777373
Qual Life Res. 2005 Jun;14(5):1333-44
16047508
Rheumatology (Oxford). 2007 Aug;46(8):1345-54
17562686
Health Econ. 2010 Jun;19(6):683-96
19504545
Arthritis Rheum. 2007 Aug 15;57(6):963-71
17665482
Pharmacoeconomics. 1995 Sep;8(3):245-52
10155620